2026 Global: Cardiac Mapping Market-Competitive Review (2032) report
Description
The 2026 Global: Cardiac Mapping Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac mapping market by geography and historical trend. The scope of the report extends to sizing of the cardiac mapping market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The cardiac mapping market is dominated by ten major companies: Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Biosense Webster (Johnson & Johnson), Koninklijke Philips N.V., Acutus Medical, Inc., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Lepu Medical Technology Co., Ltd., and Siemens Healthineers. These firms lead through robust R&D investments, strategic partnerships, and innovative product launches that address rising arrhythmia prevalence, such as atrial fibrillation and ventricular tachycardia. Abbott's EnSite X EP System provides high-density mapping with real-time anatomical insights, enhanced by its June 2025 CE Mark for the Volt Pulsed Field Ablation System achieving 99.1% pulmonary vein isolation. Medtronic's Affera Mapping and Ablation System, including the Sphere-9 catheter, reported an 88% arrhythmia-free survival rate in April 2025 trials for paroxysmal AF, while Boston Scientific's FARAPULSE platform earned FDA approval in July 2025 for persistent AF with 85.3% success post-ADVANTAGE AF trial. Biosense Webster's CARTO 3 System Version 8, launched in May 2024, offers precise 3D electroanatomical mapping integrated with ablation, solidifying its gold-standard status.
These leaders collectively hold about 97% market share, driven by minimally invasive technologies, global expansions into Asia-Pacific and emerging markets, and regulatory wins. Koninklijke Philips N.V. advances with integrated imaging-mapping solutions, while Acutus Medical focuses on non-invasive platforms like AcQMap for rapid, high-resolution arrhythmia visualization. MicroPort Scientific and Lepu Medical innovate in high-density catheters and real-time tools, leveraging OEM partnerships for broader reach in cost-sensitive regions. BIOTRONIK emphasizes biocompatible mapping systems for complex cases, and Siemens Healthineers integrates AI-driven diagnostics with mapping for enhanced workflow efficiency. Recent developments underscore competition: Stereotaxis filed for its MAGiC Sweep robotic catheter in March 2025, though not top-tier, it highlights niche advancements influencing majors. Market growth at 11.3% CAGR to USD 10.9 billion by 2034 reflects these firms' focus on pulsed field ablation (PFA), AI navigation, and computational mapping.
Strategic moves like acquisitions—Boston Scientific's Cortex for PFA mapping—and collaborations, such as Abbott with iCardio.ai, propel innovation amid a moderately consolidated landscape. These companies prioritize geographic expansion, with Asia-Pacific at 9.54% CAGR due to aging populations and investments like Fortis Healthcare's AI cath labs. Philips and BIOTRONIK target Europe via harmonized regulations, while Lepu and MicroPort intensify FDA/CE pursuits for price-competitive devices. Overall, sustained R&D, evidenced by over 85% efficacy in new PFA trials, positions these ten as pivotal in transforming cardiac procedures toward precision and safety.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac mapping market by geography and historical trend. The scope of the report extends to sizing of the cardiac mapping market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The cardiac mapping market is dominated by ten major companies: Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Biosense Webster (Johnson & Johnson), Koninklijke Philips N.V., Acutus Medical, Inc., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Lepu Medical Technology Co., Ltd., and Siemens Healthineers. These firms lead through robust R&D investments, strategic partnerships, and innovative product launches that address rising arrhythmia prevalence, such as atrial fibrillation and ventricular tachycardia. Abbott's EnSite X EP System provides high-density mapping with real-time anatomical insights, enhanced by its June 2025 CE Mark for the Volt Pulsed Field Ablation System achieving 99.1% pulmonary vein isolation. Medtronic's Affera Mapping and Ablation System, including the Sphere-9 catheter, reported an 88% arrhythmia-free survival rate in April 2025 trials for paroxysmal AF, while Boston Scientific's FARAPULSE platform earned FDA approval in July 2025 for persistent AF with 85.3% success post-ADVANTAGE AF trial. Biosense Webster's CARTO 3 System Version 8, launched in May 2024, offers precise 3D electroanatomical mapping integrated with ablation, solidifying its gold-standard status.
These leaders collectively hold about 97% market share, driven by minimally invasive technologies, global expansions into Asia-Pacific and emerging markets, and regulatory wins. Koninklijke Philips N.V. advances with integrated imaging-mapping solutions, while Acutus Medical focuses on non-invasive platforms like AcQMap for rapid, high-resolution arrhythmia visualization. MicroPort Scientific and Lepu Medical innovate in high-density catheters and real-time tools, leveraging OEM partnerships for broader reach in cost-sensitive regions. BIOTRONIK emphasizes biocompatible mapping systems for complex cases, and Siemens Healthineers integrates AI-driven diagnostics with mapping for enhanced workflow efficiency. Recent developments underscore competition: Stereotaxis filed for its MAGiC Sweep robotic catheter in March 2025, though not top-tier, it highlights niche advancements influencing majors. Market growth at 11.3% CAGR to USD 10.9 billion by 2034 reflects these firms' focus on pulsed field ablation (PFA), AI navigation, and computational mapping.
Strategic moves like acquisitions—Boston Scientific's Cortex for PFA mapping—and collaborations, such as Abbott with iCardio.ai, propel innovation amid a moderately consolidated landscape. These companies prioritize geographic expansion, with Asia-Pacific at 9.54% CAGR due to aging populations and investments like Fortis Healthcare's AI cath labs. Philips and BIOTRONIK target Europe via harmonized regulations, while Lepu and MicroPort intensify FDA/CE pursuits for price-competitive devices. Overall, sustained R&D, evidenced by over 85% efficacy in new PFA trials, positions these ten as pivotal in transforming cardiac procedures toward precision and safety.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
